AstraZeneca inhaler lags GSK drug in lung disease trial

 A new AstraZeneca inhaler for chronic lung disease has proved worse than a rival GlaxoSmithKline product in a clinical trial, a result AstraZeneca said was inconsistent with earlier findings.